Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EXQEE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-CD22- (LC:K149C)-SN36248
|
|||||
| Synonyms |
AntiCD22- (LC:K149C)-SN36248; anti-CD22-SN36248
Click to Show/Hide
|
|||||
| Organization |
Genentech, Inc
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Non Hodgkin lymphoma [ICD11:2B33]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Pinatuzumab
|
Antibody Info | ||||
| Antigen Name |
B-cell receptor CD22 (CD22)
|
Antigen Info | ||||
| Payload Name |
seco-CBI-dimer
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mal-PEG2
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugated of maleimidocaproyl with K149C site in light chain free thiol via Michael addition.
|
|||||
| Combination Type |
SN36248
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 95.70% (Day 10) | Positive CD22 expression (CD22+++/++) | ||
| Method Description |
The inhibitory activity of thio-hu anti-CD22-(LC:K149C)-SN36248 against cancer cell growth was compared with a Pinatuzumab vedotin (pina) and polatuzumab vedotin (pola) against various human cancer cell lines in vitro.
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 96.00% (Day 15) | Positive CD22 expression (CD22+++/++) | ||
| Method Description |
The inhibitory activity of thio-hu anti-CD22-(LC:K149C)-SN36248 against cancer cell growth was compared with a Pinatuzumab vedotin (pina) and polatuzumab vedotin (pola) against various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 96.70% (Day 14) | Positive CD22 expression (CD22+++/++) | ||
| Method Description |
The inhibitory activity of thio-hu anti-CD22-(LC:K149C)-SN36248 against cancer cell growth was compared with a Pinatuzumab vedotin (pina) and polatuzumab vedotin (pola) against various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Burkitt lymphoma | BJAB.Luc-22R1.2 cells | CVCL_5711 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.20% (Day 15) | Positive CD22 expression (CD22+++/++) | ||
| Method Description |
The inhibitory activity of thio-hu anti-CD22-(LC:K149C)-SN36248 against cancer cell growth was compared with a Pinatuzumab vedotin (pina) and polatuzumab vedotin (pola) against various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Burkitt lymphoma | BJAB.Luc cells | CVCL_5711 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.